Welcome to the State of California 

Office of AIDS

ADAP Management Memos 

Management Memoranda 2015

Number   Subject

Management Memo 2015-13 is being sent out to notify all ADAP EWs that two vaccines (pneumococcal conjugate vaccine and meningococcal vaccine) have been added to the ADAP formulary. The memo is also to notify EWs that two obsolete antiretroviral drugs have been removed from the formulary.

Management Memo 2015-12 announces the changes for accessing Hepatitis C treatment through ADAP

Management memorandum 2015-11 is intended to provide information to all ADAP Enrollment Workers regarding the OA-HIPP Tool. The purpose of the OA-HIPP Tool is to provide guidance regarding OA-HIPP eligibility, enrollment, re-enrollment, and recertification. Eligibility Workers may use the OA-HIPP Tool as a checklist and guide as they enroll clients into OA-HIPP. The objective of the OA-HIPP Tool is to provide guidance in the process of screening prospective OA-HIPP clients for eligibility and maintaining current required documents in clients files for annual re-enrollment and recertification.

This memo is being sent to you to provide information regarding the addition of two new Hepatitis C drugs to the ADAP Formulary [ledipasvir/sofosbuvir (Harvoni®) and ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets (Viekira Pak™ )].

Management Memo 2015-09 outlines the scope of disclosure of ADAP client information for EWs at an ADAP Enrollment Site that is a Health Care Provider, Public Health Department, and/or a Community Based Organization. Attached to the memo are Confidentiality Tables and corresponding Flowcharts.

This memo is being sent to inform all Local ADAP Coordinators and ADAP Enrollment Workers that the new qualifying poverty levels for Medi-Cal Expansion (MCE) will be effective April 17, 2015.

Additional instructions on filing tax returns with a 1095A. Included is also the letter sent out to clients regarding APTC reconciliation.

Effective April 17, 2015, ADAP grace period for MCE eligibility determination will be reinstated to its original timeframe of 45 days.

Details the extended open enrollment period for Covered California, tax penalties for individuals who choose not to obtain health insurance and provides clarification regarding amended 1095As from Covered CA. Also includes a link to the 2015 ADAP-Covered California Formulary Comparison Chart which identifies antiretroviral and hepatitis C drugs on ADAP’s formulary with those on Covered California health plan formularies.  

Effective February 27, 2015, atazanavir 300 mg/cobicistat 150 mg (Evotaz™) tablets and darunavir 800 mg/cobicistat 150 mg (Prezcobix™) tablets have been added to the ADAP formulary.

ARIES (AIDS Regional Information and Evaluation System) Consent Form is no longer required.

OA HIPP eligibility requirements for individuals who are eligible for employer based health insurance. Also references an updated OA HIPP client responsibilities document (summarizing OA-HIPP re-enrollment and recertification requirements and answers to frequently asked questions).

Details the application deadlines for new HIPP clients with Covered California plans and how existing Covered California clients should file their 2014 federal taxes.

 Prior Year ADAP Management Memos


Office of AIDS Home 

Last modified on: 7/14/2015 1:49 PM